We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM)

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability (PHATHOM) content piece image

Psychedelics have been used for millennia in both spiritual and medicinal contexts. Recently, a number of clinical successes with psychedelics have generated considerable excitement; nevertheless, mechanisms underlying their therapeutic efficacy are largely unknown.

Dr. Dölen will discuss recent evidence from her lab that MDMA targets an evolutionarily ancient mechanism shared with Octopus (Edsinger and Dolen, Current Biology 2018) and may have its therapeutic effects through its ability to reopen the social reward learning critical period (Nardou, et al., Nature, 2019).

Building on this discovery, Dr. Dölen has initiated the PHATHOM project (Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability; www.phathomproject.org), which aims to test the hypothesis that psychedelic drugs as a class act to reopen multiple critical periods across the brain, and that this property can be harnessed for therapeutic benefit.

During this webinar we will discuss:

  • Therapeutic effects and the mechanism of action of MDMA
  • The PHATHOM project and what it aims to achieve
  • What the future holds for psychedelic drugs as therapeutic agents
Gül Dölen, PhD
Gül Dölen, PhD
Associate Professor of Neuroscience, The Johns Hopkins University